TY - JOUR
T1 - Paclitaxel plus carboplatin for advanced lung cancer
T2 - Preliminary results of a Vanderbilt University Phase II Trial - LUN-46
AU - Johnson, D. H.
AU - Paul, D. M.
AU - Hande, K. R.
AU - DeVore, R. F.
PY - 1995
Y1 - 1995
N2 - Based on their good activity and minimal toxicity in non-small cell lung cancer and other cancers, we initiated a phase II trial of carboplatin plus paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in the treatment of patients with previously untreated stage IIIB and IV non-small cell lung cancer. Among 51 patients treated, the overall response rate was 27.5% (14 partial responses). Seventeen patients had stable disease, while 16 patients experienced disease progression after two cycles of treatment. Apart from myelosuppression, toxicity has been modest, with fewer than 5% of patients experiencing grade 3 or greater nonhematologic toxicity. Objective response and survival rates were modestly improved among patients given the higher of two paclitaxel doses (175 mg/m2 v 135 mg/m2). These data suggest that paclitaxel plus carboplatin warrants further study in metastatic non- small cell lung cancer.
AB - Based on their good activity and minimal toxicity in non-small cell lung cancer and other cancers, we initiated a phase II trial of carboplatin plus paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in the treatment of patients with previously untreated stage IIIB and IV non-small cell lung cancer. Among 51 patients treated, the overall response rate was 27.5% (14 partial responses). Seventeen patients had stable disease, while 16 patients experienced disease progression after two cycles of treatment. Apart from myelosuppression, toxicity has been modest, with fewer than 5% of patients experiencing grade 3 or greater nonhematologic toxicity. Objective response and survival rates were modestly improved among patients given the higher of two paclitaxel doses (175 mg/m2 v 135 mg/m2). These data suggest that paclitaxel plus carboplatin warrants further study in metastatic non- small cell lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=0029056179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029056179&partnerID=8YFLogxK
M3 - Article
C2 - 7644925
AN - SCOPUS:0029056179
SN - 0093-7754
VL - 22
SP - 30
EP - 33
JO - Seminars in oncology
JF - Seminars in oncology
IS - 4 SUPPL. 9
ER -